christine.berni@accesspharma.com

www.AccessPharma.com

2600 Stemmons Freeway
Suite 176
Dallas, TX 75207
P: 214.905.5100
F: 214.905.5101


 

Research Report| Presentation Downloads:

Access Pharma: Griffin Securities 7/30/09

Access Pharma: NextWave 12/16/09

Access Pharma: January 2010 Presentation

Disclaimer

Contact Us

Access Pharma Blog

Current Articles | RSS Feed RSS Feed

OutsideIn Research - Q&A with Jeff Davis of Access Pharma (OTCBB: ACCP) - Part 1

  
  
  
  
  
Jeffrey Davis is the CEO of Access Pharmaceuticals (OTCBB: ACCP) which is an emerging oncology-focused specialty pharmaceuticals company (January 2008 to present). The OutsideIn Research interview is broken into two sections:
  1. Part I - covers Access Pharma's strategy and its first product MuGard, which is in product launch now, and
  2. Part II - covers Access Pharma's three products in the pipeline, Cobalamin, ProLindac, and Thiarabine.

Here is Part I at OutsideIn Research.

Comments

Currently, there are no comments. Be the first to post one!
Post Comment
Name
 *
Email
 *
Website (optional)
Comment
 *

Allowed tags: <a> link, <b> bold, <i> italics

ACCP Landing Page

accp proactive